Exact Mass: 355.9909654
Exact Mass Matches: 355.9909654
Found 71 metabolites which its exact mass value is equals to given mass value 355.9909654,
within given mass tolerance error 0.05 dalton. Try search metabolite list with more accurate mass tolerance error
0.01 dalton.
Y 23684
C18H13ClN2O2S (356.03862280000004)
Silver sulfadiazine
D - Dermatologicals > D06 - Antibiotics and chemotherapeutics for dermatological use > D06B - Chemotherapeutics for topical use > D06BA - Sulfonamides C254 - Anti-Infective Agent > C29739 - Sulfonamide Anti-Infective Agent C254 - Anti-Infective Agent > C28394 - Topical Anti-Infective Agent D000890 - Anti-Infective Agents > D013424 - Sulfanilamides
(+)-Chebulic acid
(+)-Chebulic acid is found in fruits. (+)-Chebulic acid is isolated from Phyllanthus emblica (emblic). Isolated from Phyllanthus emblica (emblic). (+)-Chebulic acid is found in fruits.
Azothoate
C14H14ClN2O3PS (356.01512540000004)
O1-(4-Chlorobenzoyl)-2-[(2-furylmethyl)sulfonyl]ethanehydroximamide
9-(toluene-4-sulfonyloxy)-furo[3,2-g]chromen-7-one
2-butanoyl-3,6,8-trihydroxy-1,4-naphthoquinone 6-O-sulfate
Chebulic_acid
Chebulic acid is a natural product found in Terminalia chebula, Terminalia citrina, and Phyllanthus emblica with data available. Chebulic acid, a phenolcarboxylic acid compound isolated from Terminalia chebula, has potent anti-oxidant activity, which breaks the cross-links of proteins induced by advanced glycation end-products (AGEs) and inhibits the formation of AGEs. Chebulic acid is effective in controlling elevated metabolic parameters, oxidative stress and renal damage, supporting its beneficial effect in diabetic nephropathy[1][2]. Chebulic acid, a phenolcarboxylic acid compound isolated from Terminalia chebula, has potent anti-oxidant activity, which breaks the cross-links of proteins induced by advanced glycation end-products (AGEs) and inhibits the formation of AGEs. Chebulic acid is effective in controlling elevated metabolic parameters, oxidative stress and renal damage, supporting its beneficial effect in diabetic nephropathy[1][2].
(+)-Chebulic acid
3-(4-Bromobenzyl)-2-butyl-4-chloro-1H-imidazol-5-ylmethanol
4-(5-Cyclopropyl-1,2,4-oxadiazol-3-yl)-3-iodobenzoic acid
C12H9IN2O3 (355.96579139999994)
1,3-adamantanediacetyl dichloride
C14H16Cl4O2 (355.99043559999996)
2,6-Bis(methylthio)-3,5-diphenyl-4H-thiopyran-4-one
2-[(1,3-dioxoisoindol-2-yl)disulfanyl]isoindole-1,3-dione
5-(6-CHLORO-3-PYRIDYL)-4-[3-(TRIFLUOROMETHYL)PHENYL]-4H-1,2,4-TRIAZOLE-3-THIOL
5-(CHLOROMETHYL)-3-[3,5-DI(TRIFLUOROMETHYL)STYRYL]-1,2,4-OXADIAZOLE
5-(BENZOTHIAZOL-2-YLSULFANYLMETHYL)-4-PHENYL-4H-[1,2,4]TRIAZOLE-3-THIOL
C16H12N4S3 (356.02240720000003)
sodium bis(2-hydroxyethyl) 5-sulphonatoisophthalate
C12H13NaO9S (356.01779680000004)
Sulfabrom
C254 - Anti-Infective Agent > C29739 - Sulfonamide Anti-Infective Agent
5-broMo-3-(4-Methoxyphenyl)-1-phenyl-1H-pyrazole-4-carbaldehyde
2-[5-iodo-3-(phenylmethoxymethyl)imidazol-4-yl]acetaldehyde
2-[2-(ALLYLOXY)-1,1,2,2-TETRAFLUOROETHOXY]TETRAFLUOROETHANESULFONYL FLUORIDE
C7H5F9O4S (355.97648380000004)
7-Bromo-2-(chloroacetyl)-9,9-difluorofluorene
C15H8BrClF2O (355.94150720000005)
(S)-3,4-Dihydro-4-hydroxy-2-(3-methoxypropyl)-2H-thieno[3,2-e]-1,2-thiazine-6-sulfonamide 1,1-dioxide
MANGANESE, CHLORO[[2,2-[1,2-ETHANEDIYLBIS[(NITRILO-KN)METHYLIDYNE]]BIS[PHENOLATO-KO]](2-)]-, (SP-5-13)-
Chlorisondamine
C14H20Cl4N2+2 (356.03805200000005)
C78272 - Agent Affecting Nervous System > C66880 - Anticholinergic Agent > C66886 - Nicotinic Antagonist D018373 - Peripheral Nervous System Agents > D001337 - Autonomic Agents > D005730 - Ganglionic Blockers D018377 - Neurotransmitter Agents > D018678 - Cholinergic Agents > D018680 - Cholinergic Antagonists D002317 - Cardiovascular Agents > D000959 - Antihypertensive Agents
5-bromo-2-methoxy-N-(3-methyl-2-pyridinyl)benzenesulfonamide
C13H13BrN2O3S (355.9830208000001)
2-(4-(4-Hydroxyphenoxy)-3-iodophenyl)ethanaminium chloride
3-[1-(2,4-Dichlorophenyl)sulfonyl-2-pyrrolidinyl]pyridine
3-[3-(2,4-Dichlorophenoxy)propoxy]-6-methyl-2-nitropyridine
N-[2-chloro-5-(trifluoromethyl)phenyl]-5-pyridin-4-yl-1,3,4-thiadiazol-2-amine
1-[4-(3-Chloro-2,4,6-trifluorophenyl)sulfonyl-1-piperazinyl]ethanone
3-bromo-4-methyl-N-[(2-oxolanylmethylamino)-sulfanylidenemethyl]benzamide
CTPI-2
CTPI-2 is a third-generation mitochondrial citrate carrier SLC25A1 inhibitor with a KD of 3.5 μM. CTPI-2 inhibits glycolysis, PPARγ, and its downstream target the glucose transporter GLUT4. CTPI-2 halts salient alterations of NASH reverting steatosis, preventing the evolution to steatohepatitis, reducing inflammatory macrophage infiltration in the liver and adipose tissue, and starkly mitigating obesity induced by a high-fat diet. Antitumor activity[1][2].
4-(6-bromo-1h-indol-3-yl)-5-hydroxy-3-(3h-imidazol-4-yl)pyrrol-2-one
(1r,9r,10r,14s)-3-bromo-10,12,14-trihydroxy-13-methyl-2,8,11,13-tetraazatetracyclo[7.6.0.0²,⁶.0¹⁰,¹⁴]pentadeca-3,5,11-trien-7-one
C12H13BrN4O4 (356.01201180000004)